Trial Profile
Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Molsidomine (Primary)
- Indications Angina pectoris
- Focus Biomarker; Pharmacodynamics
- Acronyms MEDCOR
- Sponsors Therabel
- 25 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 25 Sep 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 23 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.